Literature DB >> 8769682

Characteristics of low density lipoprotein isolated from circulating immune complexes.

V V Tertov1, I A Sobenin, A N Orekhov, O Jaakkola, T Solakivi, T Nikkari.   

Abstract

Circulating immune complexes (CIC) containing low density lipoprotein (LDL) were recently found in the blood of patients with coronary atherosclerosis. In the present study, we investigated the chemical composition and physical characteristics of the lipoprotein constituents of these CIC. CIC were isolated from the blood of atherosclerotic patients by affinity chromatography using anti-human immunoglobulin G-agarose. Low density lipoprotein of these complexes (CIC-LDL) was obtained by ultracentrifugation. CIC-LDL was compared with free circulating LDL isolated from the blood plasma of the same patients. Plasma LDL was fractionated by lectin-chromatography on RCA120-agarose to obtain desialylated LDL (atherogenic) and sialylated LDL (nonatherogenic). Both CIC-LDL and desialylated LDL, but not native (sialylated) lipoprotein, induced a 1.8- to 3-fold increase in the intracellular contents of free and esterified cholesterol of cells cultured from grossly normal areas of human aorta. The sialic acid level in CIC-LDL was 1.3- and 2.1-fold lower than in desialylated or native LDL, respectively. The neutral lipid and phospholipid contents of CIC-LDL and desialylated LDL were reduced as compared to native LDL. The levels of lipid-oxidation products, thiobarbituric acid-reactive substances and hydroperoxides, were similar in all lipoprotein preparations. However, desialylated LDL and CIC-LDL had an elevated oxysterol content. Gradient ultracentrifugation revealed that CIC-LDL particles had a higher density than native LDL. The mean diameters of native, desialylated and CIC-LDL accounted for 24.0, 21.3 and 19.5 nm, respectively. Like desialylated LDL, CIC-LDL displayed a higher electrophoretic mobility compared with that of native LDL. Thus, LDL obtained from circulating immune complexes appears to be a multiple-modified lipoprotein possessing many similarities to desialylated LDL. It was also found that the LDL content of circulating immune complexes correlates well with the desialylated LDL level in human plasma but not with the total LDL concentration. We believe that desialylated LDL predominately interacts with antibodies forming immune complexes. Taken together, our findings suggest that multiple-modified desialylated LDL is the circulating autoantigen for anti-LDL autoantibodies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8769682     DOI: 10.1016/0021-9150(95)05737-4

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  10 in total

1.  Soy isoflavones reduce electronegative low-density lipoprotein (LDL(-)) and anti-LDL (-) autoantibodies in experimental atherosclerosis.

Authors:  Nágila Raquel Teixeira Damasceno; Elaine Apolinário; Fabiana Dias Flauzino; Irene Fernandes; Dulcineia Saes Parra Abdalla
Journal:  Eur J Nutr       Date:  2007-01-30       Impact factor: 5.614

2.  Diagnostic and prognostic value of low density lipoprotein-containing circulating immune complexes in atherosclerosis.

Authors:  Igor A Sobenin; Vasily P Karagodin; Alexandra Capital A Cyrillic Melnichenko; Yuri V Bobryshev; Alexander N Orekhov
Journal:  J Clin Immunol       Date:  2012-10-17       Impact factor: 8.317

Review 3.  Clinical significance of the humoral immune response to modified LDL.

Authors:  Maria F Lopes-Virella; Gabriel Virella
Journal:  Clin Immunol       Date:  2009-05-08       Impact factor: 3.969

4.  Role of Phagocytosis in the Pro-Inflammatory Response in LDL-Induced Foam Cell Formation; a Transcriptome Analysis.

Authors:  Alexander N Orekhov; Nikita G Nikiforov; Vasily N Sukhorukov; Marina V Kubekina; Igor A Sobenin; Wei-Kai Wu; Kathy K Foxx; Sergey Pintus; Philip Stegmaier; Daria Stelmashenko; Alexander Kel; Alexei N Gratchev; Alexandra A Melnichenko; Reinhard Wetzker; Volha I Summerhill; Ichiro Manabe; Yumiko Oishi
Journal:  Int J Mol Sci       Date:  2020-01-27       Impact factor: 5.923

Review 5.  Lipoprotein sialylation in atherosclerosis: Lessons from mice.

Authors:  Liming Yu; Jun Peng; Chieko Mineo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-06       Impact factor: 6.055

Review 6.  Proatherogenic Sialidases and Desialylated Lipoproteins: 35 Years of Research and Current State from Bench to Bedside.

Authors:  Alexandre Mezentsev; Evgeny Bezsonov; Dmitry Kashirskikh; Mirza S Baig; Ali H Eid; Alexander Orekhov
Journal:  Biomedicines       Date:  2021-05-25

Review 7.  Low density lipoprotein-containing circulating immune complexes: role in atherosclerosis and diagnostic value.

Authors:  Igor A Sobenin; Jukka T Salonen; Andrey V Zhelankin; Alexandra A Melnichenko; Jari Kaikkonen; Yuri V Bobryshev; Alexander N Orekhov
Journal:  Biomed Res Int       Date:  2014-06-18       Impact factor: 3.411

Review 8.  Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease.

Authors:  Alexander N Orekhov; Yuri V Bobryshev; Igor A Sobenin; Alexandra A Melnichenko; Dimitry A Chistiakov
Journal:  Int J Mol Sci       Date:  2014-07-21       Impact factor: 5.923

9.  Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect.

Authors:  Gerd Hörl; Harald Froehlich; Ulrika Ferstl; Gerhard Ledinski; Josepha Binder; Gerhard Cvirn; Tatjana Stojakovic; Michael Trauner; Christoph Koidl; Erwin Tafeit; Karin Amrein; Hubert Scharnagl; Günther Jürgens; Seth Hallström
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

10.  Signaling Pathways Potentially Responsible for Foam Cell Formation: Cholesterol Accumulation or Inflammatory Response-What is First?

Authors:  Alexander N Orekhov; Vasily N Sukhorukov; Nikita G Nikiforov; Marina V Kubekina; Igor A Sobenin; Kathy K Foxx; Sergey Pintus; Philip Stegmaier; Daria Stelmashenko; Alexander Kel; Anastasia V Poznyak; Wei-Kai Wu; Artem S Kasianov; Vsevolod Y Makeev; Ichiro Manabe; Yumiko Oishi
Journal:  Int J Mol Sci       Date:  2020-04-14       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.